A longitudinal study of serum brain-derived neurotrophic factor levels in first-episode schizophrenia
Biomarkers identified for psychosis might allow for early diagnosis, more accurate prognosis, and tailored individualized interventions. Brain-derived neurotrophic factor (BDNF) is suggested to be a likely candidate biomarker for the diagnosis and treatment evaluation in psychosis. The aims of prese...
Saved in:
Main Authors: | , , |
---|---|
其他作者: | |
格式: | Article |
語言: | English |
出版: |
2021
|
主題: | |
在線閱讀: | https://hdl.handle.net/10356/149212 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
總結: | Biomarkers identified for psychosis might allow for early diagnosis, more accurate prognosis, and tailored individualized interventions. Brain-derived neurotrophic factor (BDNF) is suggested to be a likely candidate biomarker for the diagnosis and treatment evaluation in psychosis. The aims of present study were to examine the levels of serum BDNF in both patients with first-episode psychosis (FEP) and in healthy controls for a year, and to investigate the association between BDNF with symptom severity and remission status. |
---|